Key Stats for Medpace Holdings Stock
- Price change for Medpace Holdings stock: 15%
- $MEDP Stock Price as of Jul. 22: $528
- 52-Week High: $629
- $MEDP Stock Price Target: $472
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Medpace Holdings (MEDP) stock is jumping today after the clinical research company posted Q2 numbers that beat expectations across the board.
Earnings per share came in at $4.25, topping the $4.00 analysts were looking for. Revenue landed at $707.3 million, well ahead of the $690.68 million consensus estimate. Revenue was up 17.2% from $603.3 million a year ago.
Net income jumped to $121.4 million, or $4.25 per diluted share, up from $90.3 million, or $3.10 per share, in the same quarter last year. Net income margin improved to 17.2% from 15.0%.
EBITDA also grew, rising 17.6% to $153.4 million, giving the company a 21.7% EBITDA margin.
New business awards for the quarter totaled $795.7 million, a 28.2% jump from a year ago, pushing the book-to-bill ratio to 1.13x.
That means Medpace Holdings brought in more new business than it billed out, a good sign for future revenue. Backlog, which represents future work already signed, grew to just over $3 billion, up 4.9% year over year.
On top of the earnings beat, Medpace Holdings raised its full-year guidance.
The company now expects 2026 EPS between $17.25 and $17.95, above the $17.12 analyst consensus. Full-year revenue guidance was set at $2.805 billion to $2.885 billion, also topping the $2.77 billion analysts expected.
The company also kept buying back stock, repurchasing about 706,000 shares for $294.7 million during the quarter. It still has $527 million left under its buyback program.
See analysts’ growth forecasts and price targets for Medpace Holdings stock (It’s free) >>>
What the Market Is Telling Us About Medpace Holdings Stock
The market is clearly rewarding this report.
Medpace Holdings stock has climbed just 10% over the past year, and today’s beat-and-raise quarter is creating some run from that crawl.
Beating on both revenue and earnings while also raising guidance is exactly the combination investors like to see. It suggests demand for Medpace Holdings’ clinical trial services remains strong, and management feels confident enough about the rest of the year to lift its outlook rather than just hold steady.
There’s a small wrinkle worth noting. Over the past 90 days, analysts issued 3 positive EPS revisions but 5 negative ones, meaning sentiment heading into this report was a bit mixed.
Today’s results may go a long way toward flipping that trend, since the company delivered exactly the kind of quarter that tends to win skeptics over.
For now, Medpace Holdings stock looks like it’s benefiting from strong execution, healthy new business growth, and a management team willing to raise the bar for the rest of 2026.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Medpace Holdings Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
